undamentalytics Newsletter
Sign in

Protagonist Therapeutics, Inc cash flow statement

In fiscal 2025, Protagonist Therapeutics, Inc's operations generated $57.7m of cash; it spent $1.6m on capital projects, leaving free cash flow of $56.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations4−50−42−72−108−108−7018458131
Depreciation and amortisation0111111112
Stock-based pay4788162429384650
Capital spending1010111121
Free cash flow3−50−42−73−109−109−7118356131
Free cash flow after stock pay−1−57−51−81−125−133−1001451081
Shares issued—234213124—108———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: PHAT vs PTGXPTGX vs SNDXPTGX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Protagonist Therapeutics, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Protagonist Therapeutics, Inc.